Log in
CVE:ERG

16611 (ERG.V) Stock Forecast, Price & News

C$0.30
0.00 (0.00 %)
(As of 02/27/2018)
Add
Today's Range
C$0.30
Now: C$0.30
C$0.30
50-Day Range
C$0.30
MA: C$0.30
C$0.30
52-Week Range
C$0.22
Now: C$0.30
C$0.30
Volume2,000 shs
Average Volume83,684 shs
Market CapitalizationC$21.39 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ergoresearch Ltd. operates in the healthcare sector. The Company manufactures and sells custom foot orthotics and general orthotics, and develops durable medical equipment for the orthopedic market. The Company is engaged in development of orthopedic solutions and products impacting pain management. The Company's products are non-invasive and non-toxic biomechanical devices, which feature patient benefits that are supported by clinical proof and scientific data. The Company designed and commercialized WebFit, a custom-fit orthotics manufacturing software program, and OdrA, an orthotic device. Its range of foot orthotics includes WebFit-Diabetes, WebFit-Gonosteoarthritis and WebFit. Its products also include podo-barometric sensor pads and scanners, and three dimensional (3d) scanner. The Company uses numerical control machine tools to manufacture its foot orthotics. It has approximately 10 laboratories.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
Phone+1-514-9313355
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market CapC$21.39 million
Next Earnings DateN/A
OptionableNot Optionable
C$0.30
0.00 (0.00 %)
(As of 02/27/2018)
30 days | 90 days | 365 days | Advanced Chart

Receive ERG News and Ratings via Email

Sign-up to receive the latest news and ratings for ERG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











16611 (ERG.V) (CVE:ERG) Frequently Asked Questions

What stocks does MarketBeat like better than 16611 (ERG.V)?

Wall Street analysts have given 16611 (ERG.V) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 16611 (ERG.V) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are 16611 (ERG.V)'s key executives?

16611 (ERG.V)'s management team includes the following people:
  • Sylvain Boucher, President, Chief Executive Officer, Director
  • Dominique Boudreau, Vice President - Finance
  • Frederic Petit, Vice President - Operations
  • Danielle Boucher, Vice- President of Clinique du Pied Equilibre, Director
  • Gilles Laporte, Director
  • Catherine Chamouton, Independent Director
  • Michel Pierron, Independent Director
  • Francois Tellier, Independent Director

What is 16611 (ERG.V)'s stock symbol?

16611 (ERG.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ERG."

How do I buy shares of 16611 (ERG.V)?

Shares of ERG and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is 16611 (ERG.V)'s stock price today?

One share of ERG stock can currently be purchased for approximately C$0.30.

How big of a company is 16611 (ERG.V)?

16611 (ERG.V) has a market capitalization of C$21.39 million.

What is 16611 (ERG.V)'s official website?

The official website for 16611 (ERG.V) is www.ergoresearch.com.

How can I contact 16611 (ERG.V)?

16611 (ERG.V)'s mailing address is 2101 Le Carrefour Blvd Suite 200, LAVAL, QC H7S 2J7, Canada. The company can be reached via phone at +1-514-9313355.

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.